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Abstract
Aims—AMPD1 c.34C>T (rs17602729) polymorphism results in AMPD1 deficiency. We 
examined the association of AMPD1 deficiency and variability of hemodynamic response to 
regadenoson.
Subjects & methods—Genotyping for c.34C>T was performed in 267 patients undergoing 
regadenoson cardiac stress testing.
Results—Carriers of c.34C >T variant exhibited higher relative changes in systolic blood 
pressure (SBP) compared with wild-type subjects ([%] SBP change to peak: 12 ± 25 vs 5 ± 13%; p 
= 0.01) ([%] SBP change to nadir: −3 ± 15 vs −7 ± 11%; p = 0.04). Change in heart rate was 
similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; 
p = 0.04).
Conclusion—AMPD1 deficiency may be involved in the modulation of regadenoson’s systemic 
effects.
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AMPD1 c.34C>T (rs17602729) is a polymorphism present in 12–18% of Caucasians and 
19% of African–Americans [1,2]. This variant results in the substitution of cytosine for 
thymidine, leading to a premature stop codon and substantially diminished enzymatic 
function [2,3]. AMPD1 deficiency leads to reduced clearance of adenosine monophosphate 
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(AMP) and increased production of adenosine in skeletal muscles. The heterozygous 
population exhibits partial enzymatic deficiency. Although carriers of this variant are 
frequently asymptomatic and phenotypically similar to wild types (CC), carrier status, both 
homozygous (TT) and heterozygous (CT) has been associated with myalgias or weakness 
after prolonged exercise [4] and increased blood flow response to sprint exercise [5].
Adenosine has been the principle agent used in pharmacological cardiac stress tests due to 
its effects on coronary vasodilation. By stimulating adenosine A2A receptors on arteriolar 
vascular smooth muscle cells, adenosine induces coronary arterial vasodilation and 
myocardial hyperemia, the desired cardiac state for myocardial perfusion imaging (MPI). 
The nonselective activation of A1, A2B and A3 receptors by adenosine, however, can lead to 
adverse effects including nausea, chest pain, dyspnea and less commonly, bronchospasm and 
heart blocks [6,7]. In 2008, regadenoson, an adenosine analogue and selective A2A 
adenosine receptor agonist was approved by the US FDA [8]. Regadenoson has since rapidly 
replaced adenosine during MPI because of desirable factors including a longer half-life, 
uniform dosing and ease of administration as a rapid bolus. In contrast to adenosine, 
regadenoson achieves myocardial hyperemia quicker and maintains it longer, attributes that 
make it optimal for radionuclide MPI [9]. Adenosine causes a sympathetic increase in the 
heart rate (HR), and systolic blood pressure (SBP), along with a drop in the diastolic blood 
pressure [10]. Factors that exacerbate or mitigate this physiologic response have been poorly 
studied.
The effects of genetic polymorphisms on variation in response to in vivo administration of 
regadenoson have not been studied. We hypothesized that carriers of the AMPD1 c.34C>T 
variant allele linked to AMPD1 deficiency exhibit an altered hemodynamic response to A2A 
receptor stimulation by regadenoson.
Subjects & methods
Patients
The study protocol was approved by the Indiana University institutional review board. 
Written informed consent was obtained from all participants.
Subjects who were scheduled for resting regadenoson nuclear stress testing were eligible to 
be enrolled in this study. Subjects who underwent a combination of exercise and nuclear 
pharmacologic stress testing with regadenoson were excluded from analysis. Data on 
demographics, medical history, family history, risk factors and dietary history were 
collected.
Genotyping
Genomic DNA was extracted by using the Qiagen Flexigene DNA Kit #51206 following the 
protocol for isolation of DNA from 100–500 µl buffy coat (Germantown, USA). AMPD1 c.
34C>T (rs17602729) was analyzed using an open array genotyping platform (Life 
Technologies, NY, USA) according to the manufacturer’s instructions. Alleles of interest 
were amplified by using sequence-specific primers as well as two allele-specific TaqMan® 
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probes (Applied Biosystems, CA, USA). Allelic discrimination was used to determine 
individual genotypes.
Regadenoson administration
A standard dose of 0.4 mg of regadenoson was administered through a peripheral 
intravenous line over a period of 10 s, followed by a saline flush of 5 ml over another 10 s.
Study measurements
Hemodynamic parameters, including SBP and HR, were measured prior to regadenoson 
infusion, then at 1 min intervals over a period of 5 min thereafter. Self-reported side effects 
were recorded. Primary outcomes were [1] change in HR [2], change in SBP to peak (both 
absolute and relative [%]) and [3] change in SBP to nadir (both absolute and relative [%]) 
postregadenoson administration. Change in HR was defined as the difference between the 
peak postadministration HR and the HR prior to regadenoson administration (baseline HR). 
Absolute change in SBP to peak was defined as the difference between the peak 
postadministration SBP and the baseline SBP. Likewise, absolute change in SBP to nadir 
was defined as the difference between the nadir postadministration SBP and the baseline 
SBP. Percentage [%] change was calculated by dividing the absolute change by the baseline 
SBP and multiplying the result by a 100. Secondary outcomes included the incidence of side 
effects reported by patients (nausea, abdominal pain, chest pain, dyspnea, dizziness, flushing 
and headache).
Statistical analysis
Statistical analyses were performed by using SPSS software, version 21.0 (IBM, IL, USA). 
Statistical significance was defined as p-value of less than 0.05. All statistical tests were 
two-sided, and values are represented as the mean ± standard deviation, unless otherwise 
indicated. Unpaired two-sided Student’s t-test was used to compare normally distributed 
continuous variables. Categorical variables were compared by using the chi-square test. 
AMPD1 genotypes (CC and CT + TT) were included in forward stepwise multivariate linear 
regression analysis, along with clinical variables associated with p < 0.1 in univariate 
analysis.
Results
The study population consisted of 267 individuals who underwent regadenoson stress 
testing, 55% of whom were females. The mean age was 58 years, and the majority was 
Caucasian [72.0%]. Baseline patient characteristics are summarized in Table 1. Two patients 
were homozygous for the AMPD1 T variant allele, 40 were heterozygous and 225 were wild 
type. Distribution of genotypes was consistent with Hardy–Weinberg equilibrium (p > 0.05). 
Carriers of the T allele, including homozygous and heterozygous individuals, were analyzed 
as a single group, and compared with the wild-type group, unless otherwise indicated.
There was no significant difference in baseline, peak and nadir SBP, and baseline and peak 
HR in the CT + TT group when compared with the CC group (Figure 1). The relative rise in 
SBP (% SBP change to peak) was significantly higher in the carrier group as compared with 
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the wild-type group (12 ± 25 vs 5 ± 13%; p = 0.01) (Figure 2A), as was the absolute rise in 
SBP (SBP change to peak: 14 ± 28 vs 6 ± 18 mm; p = 0.02) (Figure 2C). There was no 
significant difference in the absolute drop in SBP (SBP change to nadir: −11 ± 17 vs −5 ± 18 
mm; p = 0.08) between both groups (Figure 2C), but the relative decrease in SBP was 
significantly different (% SBP change to nadir: −7 ± 11 vs −3 ± 15%; p = 0.04) (Figure 2A). 
HR change did not differ significantly (31 ± 14 vs 30 ± 14 bpm; p = 0.6). In a multivariate 
linear regression analysis, age, gender, hyperlipidemia and smoking significantly affected 
the association between [%] SBP change to peak and AMPD1 genotype (Table 2). The same 
variables, with the exception of smoking, affected the absolute SBP change to peak (Table 
2), while both relative and absolute SBP change to nadir were only affected by age (Table 2). 
After accounting for confounding variables, T allele carriers remained significantly 
associated with a more elevated [%] change in SBP to peak (p = 0.009) (Table 2) and with a 
lesser decrease in [%] SBP change to nadir (p = 0.044) (Table 2). The absolute SBP change 
to peak continued to be significant (p = 0.012) (Table 2), while the absolute SBP change to 
nadir remained nonsignificant (p = 0.061) after multivariate adjustment (Table 2). 
Multivariate linear regression analysis of HR change and AMPD1 genotype demonstrated 
significant association of previous percutaneous coronary intervention (PCI), systolic heart 
failure, age and gender with HR change (Table 2). After adjustment of significant covariates, 
AMPD1 c.34C>T polymorphism was not significantly associated with mean HR change (p 
= 0.554).
Secondary outcomes measured included the incidence of side effects after regadenoson 
administration. Side effects reported by patients included nausea, abdominal pain, chest 
pain, dyspnea, dizziness, flushing and headache. Subjects were categorized in two groups: 
[1] no side effects reported and [2] one or more side effects reported. The incidence of side 
effects was significantly increased in carriers (CT + TT) as compared with the wild-type 
group (CC) (39/42 [93%] vs 182/225 [81%]; likelihood ratio [+] = 4.2; p = 0.04; odds ratio 
= 3.1; 95% CI: 0.91–10.4) (Figure 3). There was an increased incidence of all side effects 
except chest and abdominal pain in the carrier group. The incidence of side effects increased 
with every additional T allele, exhibiting a gene-dose effect (Figure 3).
Discussion
AMPD1 mediates the transformation of AMP into inosine monophosphate in the cytosol of 
skeletal muscle cells. Catalysis by AMPD1 plays an important role in the purine salvage 
nucleotide cycle and is a crucial step in the regeneration of energy during states of ischemia. 
In response to hypoxic states, tissue cells become dependent on oxidative phosphorylation in 
an attempt to meet increasing energy demands. This results in an increased production of 
AMP, which is in turn dephosphorylated by 5’-nucleotidase to form adenosine [2]. 
Adenosine has both direct and indirect downstream effects. By inducing smooth muscle 
relaxation and coronary arterial vasodilation via A2A receptor binding, adenosine improves 
blood flow and oxygen delivery [2,11]. Stimulation of A1 receptor by adenosine induces 
negative inotropy and chronotropy, thereby minimizing oxygen demand [2,9]. In addition to 
these direct vasomotor effects, adenosine stimulates carotid-body chemoreceptors and 
sympathetic afferent nerves resulting in systemic vasoconstriction. This complex mechanism 
leads to an overall increase in blood pressure and HR [10].
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AMPD1 c.34C>T is a common genetic polymorphism, found in 12–18% of Caucasians, 2% 
of whom are homozygous [1,2] and leads to functional AMPD1 deficiency. Lack of AMPD1 
in skeletal muscles reduces the ability to regenerate ATP stores, and may therefore result in 
decreased exercise capacity and symptoms of muscle fatigue [12,13]. Forearm blood flow in 
response to transient ischemia is increased significantly in T variant allele carriers when 
measured using venous occlusion plethysmography [14]. Femoral artery blood flow 
measured by ultrasonography is also increased in subjects with AMPD1 deficiency during 
cycling sprint exercise with more rapid recovery postexercise, but lower peak power, as 
compared with normal subjects, an effect that has been attributed to an AMPD1-dependent 
increase in adenosine formation during exercise [5]. Sabina et al. reported a 16-fold increase 
in postexercise adenosine levels in muscle biopsies obtained from subjects with AMPD1 
deficiency compared with a twofold increase in controls [12]. Consistent with these findings, 
lower prevalence of AMPD1 T variant allele has been documented in top-level endurance 
athletes as compared with controls [1,15].
In this study, we examine the effects of regadenoson on SBP and HR among patients that 
carry the T variant allele in the context of pharmacologic cardiac stress testing. We found 
that in response to regadenoson, carriers (CT + TT) exhibited a higher relative rise in SBP at 
its peak and a smaller relative drop in SBP at its lowest measurement. However, HR changes 
did not differ between both groups (31 ± 14 vs 30 ± 14 bpm; p = 0.6). Since absolute 
changes in SBP are affected by baseline measurements of SBP, the use of relative [%] SBP 
change allows adjustment for the differences in the baseline measurements. It is therefore 
likely a more accurate reflection of the magnitude of change in SBP, whether to peak or to 
nadir. Among T allele carriers, we observed a significant difference in SBP change in 
response to regadenoson, with higher relative rise in SBP and a smaller relative drop in SBP. 
In view of the complex effects of adenosine and its analogues, multiple mechanisms may 
explain this observation. Activation of A2A receptors triggers a state of hyperemia in the 
myocardium and induces sympathetic excitation [9]. AMPD1 is present in both skeletal 
muscle cells [16], as well as myocardium [17], and could therefore influence the A2A-
mediated response during MPI. Kalsi et al. have demonstrated decreased AMPD activity in 
human myocardium harvested at time of left ventricular assist device implantation or heart 
transplant in T allele carriers with advanced heart failure as compared with wild-type 
controls [18]. Klinger et al. described two potential mechanisms involved in the vasodilatory 
effect of adenosine on endothelial cells. The binding of adenosine to A2A receptors on 
endothelial cells may trigger an internal signaling pathway that activates nitric oxide 
synthase, resulting in increased vasodilation. Adenosine is also thought to have an additional 
direct vasodilatory effect on arterial smooth muscle cells [11]. Sympathetic activation causes 
peripheral vasoconstriction, triggering augmented local endogenous adenosine production in 
response to a state of increased demand. In addition, stimulation of A2A receptors in atrial 
myocytes results in ryanodine receptor phosphorylation, and release of Ca2+ from 
sarcoplasmic reticulum, possibly contributing to the rise in HR consistently observed with 
regadenoson administration [19,20].
AMPD1 deficiency leads to accumulation of intracellular AMP during hypoxia. Increase in 
AMP/ATP ratio has been demonstrated to result in activation of AMP-activated protein 
kinase during hypoxia and result in pulmonary vasoconstriction [21]. While not previously 
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studied, alteration of AMP-activated protein kinase activity could occur in AMPD1-deficient 
subjects, and possibly influence the vasoactive response to A2A stimulation in vascular 
smooth muscle cells. Activation of AMP-activated protein kinase has been shown to inhibit 
nitric oxide-mediated aortic vascular smooth muscle cell relaxation [22]. Variability in 
peripheral vasoconstriction may in part explain the increase in SBP without significant 
difference in HR response among AMPD1-deficient subjects.
The HR response was not significantly different across the different AMPD1 genotypes, 
possibly because the resulting tachycardia is predominantly influenced by ryanodine 
receptor activation in the sinus nodal tissue.
The majority of adenosine’s side effects are thought to be secondary to its vasodilatory 
properties on vessels of the skin, brain and abdominal viscera, leading to flushing, nausea, 
headache and abdominal pain respectively [23]. In our study, we demonstrate a higher rate 
and higher likelihood for the occurrence of side effects from regadenoson administration in 
T allele variant carriers as compared with wild-type individuals. Interestingly, the order of 
side effect incidence was identical in both groups, with dyspnea, dizziness and flushing (in 
descending order) being the most common (Figure 3). Increased incidence of adenosine-
specific side effects with in vivo administration of exogenous adenosine analogues in 
AMPD1-deficient patients may be the result of adenosine accumulation and activation of 
non-A2A adenosine receptors.
With regards to the FDA warning issued in November 2013 concerning the increased 
incidence of fatal myocardial infarction in patients receiving regadenoson or adenosine for 
cardiac nuclear stress tests, our study population, whether carriers of the c.34C>T mutation 
or wild type for that polymorphism, had no occurrences of adverse myocardial infarction. 
Continuous monitoring of electrocardiograms during regadenoson stress testing did not 
show any instances of AV nodal blockade in all the subjects tested.
Limitations of our study include a small number of homozygous individuals for c.34C>T 
and various co-morbidities that could account for unadjusted confounding in our analysis. 
The disparity in the racial groups (Caucasian and African–American) between carriers and 
noncarriers of the T allele is likely related to their prevalence in our geographic location, and 
the prevalence of the carrier state in general. Additionally, race was included in the 
multivariate analysis and did not significantly affect hemodynamic response (both SBP and 
HR). Further studies will be required before conclusions can be drawn whether pretest 
determination of AMPD1 genotype would be helpful prior to performance of regadenoson 
stress testing, in specific further analysis of whether altered response to regadenoson 
influences the sensitivity or specificity of pharmacologic MPI in diagnosis of coronary 
ischemia.
Conclusion
Regadenoson has become the predominantly used agent in pharmacologic MPI, yet its 
interplay with native adenosine metabolism is incompletely understood and merits further 
investigation. Our study suggests that carriers of the AMPD1 c.34C>T variant exhibit an 
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exaggerated response to regadenoson and demonstrate an increased likelihood of adverse 
side effects. Further studies are needed to elucidate the association of AMPD1 variants and 
the phenotypic response to regadenoson stress testing, as well as sensitivity and specificity 
of MPI.
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Executive summary
• Common genetic polymorphisms may play a role in the hemodynamic response 
to regadenoson during cardiac stress testing.
• AMPD1 deficiency resulted in an altered systemic response to regadenoson, 
with the involved subjects exhibiting higher SBP after regadenoson 
administration.
• Carriers of the AMPD1 T variant allele were more likely to develop side effects 
after regadenoson administration.
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Figure 1. Systolic blood pressure and heart rate response to regadenoson
(A) SBP at baseline, peak and nadir in wild-type and carrier groups. (B) SBP at baseline, 
peak and nadir in wild-type, heterozygous and homozygous groups. (C) Baseline HR and 
peak HR in wildtype and carrier groups. (D) Baseline HR and peak HR in wild-type, 
heterozygous and homozygous groups.
HR: Heart rate; SBP: Systolic blood pressure.
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Figure 2. Absolute and percentage systolic blood pressure change in response to regadenoson
(A) Percentage SBP change to peak and nadir in wild-type and carrier groups. (B) 
Percentage SBP change to peak and nadir in wild-type, heterozygous and homozygous 
groups. (C) Absolute SBP change to peak and nadir in wild-type and carrier groups. (D) 
Absolute SBP change to peak and nadir in wild-type, heterozygous and homozygous groups.
SBP: Systolic blood pressure.
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Figure 3. Incidence of side effects following regadenoson administration
(A) Incidence of side effects following regadenoson administration in carrier and wild-type 
groups. (B) Incidence of side effects following regadenoson administration in homozygous, 
heterozygous and wild-type groups.
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Table 2
Multivariate analyses of systolic blood pressure and heart rate.
Hemodynamic response to
regadenoson
Variable Effect size CI p-value
Percentage SBP change to peak AMPD1 (CT + TT) 7.02 (1.78–12.26) 0.009
Age −0.26 (−0.44 to −0.07) 0.007
Male gender −5.39 (−9.13 to −1.64) 0.005
Hyperlipidemia −4.44 (−8.61 to −0.27) 0.037
Smoking 4.041 (0.01–8.08) 0.05
Absolute SBP change to peak AMPD1 (CT + TT) 8.7 (1.95–15.46) 0.012
Age −0.32 (−0.55 to −0.08) 0.018
Male gender −6.05 (−10.88 to −1.26) 0.014
Hyperlipidemia −6.58 (−11.92 to −1.24) 0.016
Percentage SBP change to nadir AMPD1 (CT + TT) 4.18 (0.11–8.24) 0.044
Age −0.21 (−0.35 to −0.07) 0.004
Absolute SBP change to nadir AMPD1 (CT + TT) 5.58 (−0.27–11.42) 0.061
Age −0.29 (−0.49 to −0.09) 0.005
HR change AMPD1 (CT + TT) 1.31 (−3.04–5.65) 0.554
Age −0.21 (−0.36 to −0.05) 0.008
Male gender −4.15 (−7.32 to −0.98) 0.011
Systolic heart failure −7.48 (−12.49 to −2.48) 0.004
Prior PCI −5.35 (−9.21 to −1.49) 0.007
HR: Heart rate; PCI: Percutaneous coronary intervention; SBP: Systolic blood pressure.
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